Climb Bio, Inc. Common Stock (CLYM) is a publicly traded Healthcare sector company. As of May 21, 2026, CLYM trades at $10.52 with a market cap of $565.73M and a P/E ratio of -11.69. CLYM moved +9.33% today. Year to date, CLYM is +197.18%; over the trailing twelve months it is +748.39%. Its 52-week range spans $1.05 to $12.48. Analyst consensus is strong buy with an average price target of $19.67. Rallies surfaces CLYM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Climb Bio, Inc. Common Stock (CLYM) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. CLYM moved +9.33% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $10.52 |
| Market Cap | $565.73M |
| P/E Ratio | -11.69 |
| EPS | $-0.88 |
| Dividend Yield | 0.00% |
| 52-Week High | $12.48 |
| 52-Week Low | $1.05 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-59.85M |
| Gross Margin | 0.00% |
13 analysts cover CLYM: 0 strong buy, 13 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $19.67.